American Express: A Provisional Assessment

The instrument has registered a total return of 163% over the preceding five years (as of February 27th), a statistically pleasing figure, yet one that feels… provisional. It currently trades 20% below its recent peak, a declivity that invites scrutiny, though not necessarily action. One should not, under any circumstances, rush. The market operates on its own internal clock, a mechanism perpetually out of sync with human comprehension.

Optics and Oddities: A Spot of Luck for Lumentum & Coherent

The arrangement, you see, isn’t merely a case of benevolent largesse. Nvidia, in a move that smacks of rather clever foresight, is securing access to these companies’ advanced laser components. These aren’t your garden-variety beams of light, you understand. They’re the vital organs of the new AI factories, ensuring everything runs smoothly and doesn’t consume power at a rate that would make an electricity company weep with joy. A dashedly clever bit of engineering, what!

Bloom Energy: A Question of Valuation

Since last March, the company’s stock (BE 0.80%) has experienced a substantial increase. An investment of $10,000 made a year ago would now be worth $67,100 as of March 2nd. This is not, of course, a reflection of an equivalent increase in intrinsic value, but rather a demonstration of market sentiment.

AI Hype? Let’s Talk Money, Shall We?

Bloomberg’s been digging around, and apparently 23% of major credit investors surveyed by BofA are most concerned about an AI bubble. A measly 10% are losing sleep over the idea that AI will render us all obsolete. Which, let’s be real, is a relief. I mean, I’m perfectly capable of self-sabotage without the help of a super-intelligent algorithm, thank you very much.

Terns Pharma: Boxer Capital’s Bet (and My Coffee Needs)

Boxer Capital now owns 3.32% of Terns, which, in the grand scheme of a $456.88 million portfolio, is… noticeable. It’s like adding a really good side dish to a perfectly adequate meal. Their top holdings? TNGX ($96.36M), RVMD ($31.86M), KOD ($31.76M), KYMR ($25.61M), and CELC ($22.44M). Basically, they’re all in on the alphabet soup of biotech.

The Cancer Coin: A Safer Bet

There’s a little company called ImmunityBio (IBRX +1.50%). They’re making a bit of a splash, all bubbly and bright, like a fizzy drink. Shares have zoomed upwards, a rather dizzying climb. But a splash, my friends, can quickly become a puddle. And puddles, well, they’re easily stepped over. While they seem promising, if you’re looking to build a proper treasure chest, a sturdy, reliable ship is what you need, not a leaky dinghy.

Bonds & Breadcrumbs: A Pragmatic Look

These aren’t grand schemes for building empires. They’re for those of us who simply want to hold onto what little we’ve managed to gather, to see a modest return without risking it all on the whims of the market. A quiet corner, if you will, in a world that rarely offers such things.

MercadoLibre: A Question of Profit

A more pertinent inquiry, one rarely voiced amidst the daily fluctuations, is this: what, realistically, might MercadoLibre become by 2029? Not in terms of its share price—a phantom number susceptible to whims—but in terms of its fundamental character, its capacity for genuine profit, and its strategic position within a continent riddled with instability.

Chips and Folly: A Semiconductor Observation

The implication, naturally, is that silicon will continue to be the more tangible beneficiary of this digital fever dream. Software, one suspects, is viewed as rather too easily replicated by the very machines it purports to create. A somewhat unsettling thought, but perfectly in keeping with the times.